Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial
Influenza and Other Respiratory Viruses · 2024-05 · 18 (5)
DOI: 10.1111/irv.13302 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 06.05.2024. Verfasst von Hideyuki Ikematsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ricerca Clinica, Fukuoka, Japan. Hauptthemen laut MEDLINE: Influenza, Human, Pyridones, Antiviral Agents, Triazines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd.
Abstract (Originalsprache)
Background
The transmission of influenza virus in households, especially by children, is a major route of infection. Prior studies suggest that timely antiviral treatment of ill cases may reduce infection in household contacts. The aim of the study was to compare the effects of oseltamivir (OTV) and baloxavir marboxil (BXM) treatment of index cases on the secondary attack rate (SAR) of influenza within household.
Methods
A post hoc analysis was done in BLOCKSTONE trial—a placebo‐controlled, double‐blinded post‐exposure prophylaxis of BXM. Data were derived from the laboratory‐confirmed index cases' household contacts who received placebo in the trial and also from household members who did not participate in the trial but completed illness questionnaires. To assess the SAR of household members, multivariate analyses adjusted for factors including age, vaccination status, and household size were performed and compared between contacts of index cases treated with BXM or OTV.
Results
In total, 185 index cases (116 treated with BXM and 69 treated with OTV) and 410 household contacts (201 from trial, 209 by questionnaire) were included. The Poisson regression modeling showed that the SAR in household contacts of index cases treated with BXM and OTV was 10.8% and 18.5%, respectively; the adjusted relative reduction in SAR was 41.8% (95% confidence interval: 1.0%–65.7%, p = 0.0456) greater with BXM than OTV. Similar reductions were found in contacts from the trial and those included by questionnaire.
Conclusion
BXM treatment of index cases appeared to result in a greater reduction in secondary household transmission than OTV treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ricerca Clinica, Fukuoka, Japan.
- Biostatistics Center, Shionogi & Co., Ltd, Osaka, Japan.
- Department of Information Security, University of Nagasaki, Nagasaki, Japan.
- Medical Affairs Department, Shionogi & Co., Ltd, Osaka, Japan.
- Data Science Department, Shionogi & Co, Ltd, Osaka, Japan.
- Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Virginia, USA.
ORCID-Profile: Takamichi Baba
Förderung
- Shionogi & Co., Ltd
Zitieren
APA
Ikematsu, H., Baba, T., Saito, M. M., Kinoshita, M., Miyazawa, S., Hata, A., Nakano, S., Kitanishi, Y., & Hayden, F. G. (2024). Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial. Influenza and Other Respiratory Viruses, 18(5). https://doi.org/10.1111/irv.13302
Vancouver
Ikematsu H, Baba T, Saito MM, Kinoshita M, Miyazawa S, Hata A, et al. Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial. Influenza and Other Respiratory Viruses. 2024;18(5). doi:10.1111/irv.13302
BibTeX
@article{Ikematsu2024,
author = {Ikematsu, Hideyuki and Baba, Takamichi and Saito, Masaya M and Kinoshita, Masahiro and Miyazawa, Shogo and Hata, Ayano and Nakano, Saki and Kitanishi, Yoshitake and Hayden, Frederick G},
title = {Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
volume = {18},
number = {5},
doi = {10.1111/irv.13302}
}
EUVIMED